FORMULATION AND EVALUATION OF SOLUBILITY ENHANCED IN SITU GELLING EYE DROPS OF LOTEPREDNOL ETABONATE

  • NIKITA PRADEEP KHANDELWAL Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa.
  • PRASHANT BHIDE Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa.
  • REESHWA NACHINOLKAR Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa.

Abstract

Objective: The aim of the present study is to improve the aqueous solubility and develop in situ gelling eye drops of loteprednol etabonate. Beta-cyclodextrin (β-CD)-assisted solubility enhancement was attempted and phase solubility studies were carried out.


Methods: The kneading technique was used to formulate drug/β-CD inclusion complexes with a ratio of 1:1. In situ gelling ophthalmic sol–gel systems were then developed. Ion-sensitive and pH-dependent trigger mechanisms were targeted. The former type was based on increasing gellan gum concentration, to formulate three systems F1, F2, and F3. The latter pH-dependent systems were formulated using a constant concentration of Carbopol 971P NF and varying concentrations of hydroxypropyl methylcellulose (HPMC) K4 M and HPMC K15M grades giving formulations F4, F5, and F6. All six formulations were subjected to physicochemical evaluation for clarity and appearance, texture analysis, pH, viscosity, isotonicity, in vitro gelation, drug content determination, and microbiological tests (sterility testing and effectiveness of preservative) which were also conducted.


Results: All the six formulations passed the analytical tests, with F2 and F4 emerging as the optimized formulations. Eight hour in-vitro drug release carried out in a fabricated diffusion cell revealed the release to a concentration dependent controlled one. One month stability studies at 40°C and 75% RH of the optimized formulations proved their robustness.


Conclusion: Extensive studies carried out revealed the optimized formulation for each category of sol-gel systems. Formulations F2 and F4 were found to be these optimized formulations.

Keywords: Loteprednol etabonate, Beta-cyclodextrin, Solubility, In situ gelling

Author Biography

NIKITA PRADEEP KHANDELWAL, Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa.

assistent professor

department of pharmaceutics

References

1. Harish NM, Prabhu P, Charyulu RN, Gulzar MA, Subrahmanyam EV. Formulation and evaluation of in situ gels containing clotrimazole for oral candidiasis. Indian J Pharm Sci 2009;71:421-7.
2. Merkli A, Tabatabay C, Gurny R. Biodegradable polymers for the controlled release of ocular drugs. Prog Polym Sci 1998;23:563-80.
3. Swarbrick J. Complexation: Cyclodextrins. In: Encyclopedia of Pharmaceutical Technology. 3rd ed., Vol. 1. New York: Informa Healthcare Inc.; 2007. p. 171-97.
4. Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-51.
5. Patil JS, Kadam DV, Marapur SC, Kamalapur MV. Inclusion complex system; a novel technique to improve the solubility and bioavailability of poorly soluble drugs: A review. Int J Pharm Sci Rev Res 2010;2:29-34.
6. Sweetman SC. Corticosteroids. Martindale: The Complete Drug Reference. 36th ed. London: RPS Publishing; 2009. p. 1490-537.
7. Bajaj IB, Survase SA, Saudagar PS, Singhal RS. Gellangum: Fermentative production, downstream processing and applications. Food Technol Biotechnol 2007;45:341-54.
8. Carter SJ. Ophthalmic products. In: Cooper and Gunn’s dispensing for pharmaceutical students. 12th ed. New Delhi: CBS Publishers; 2013. p. 635-8.
9. Comstock T, DeCory H. Advances in corticosteroid therapy for ocular inflammation: Loteprednoletabonate. Int J Inflam 2012;789623:1-11.
10. Loftsson T, Hreinsdóttir D, Másson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18-28.
11. Paulsson M, Hägerström H, Edsman K. Rheological studies of the gelation of deacetylated gellan gum (Gelrite) in physiological conditions. Eur J Pharm Sci 1999;9:99-105.
12. Bodor N, Drustrup J, Wu W. Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate. Pharmazie 2000;55:206-9.
13. Davies NM, Wang G, Tucker IG. Evaluation of hydrocortisone/ hydroxypropyl-?-cyclodextrin solution for ocular drug delivery. Intl J Pharm 1997;156:201-9.
14. Sanz Taberner T, Martín-Villodre A, Pla-Delfina JM, Herráez JV. Consistency of carbopol 971-P NF gels and influence of soluble and cross-linked PVP. Int J Pharm 2002;233:43-50.
15. Deulker A, Gude R, Sancoalcar A, Vaidya S. Formulation development and evaluation of long acting ophthalmic in situ gelling system of dorzolamide hydrochloride. Int J Drug Dev Res 2013;5:156-63.
16. Mohan EC, Kandukuri JM, Allenki V. Preparation and evaluation of in situ gels for ocular drug delivery. J Pharm Res 2009;2;1089-94.
17. Liu Y, Liu J, Zhang X, Zhang R, Huang Y, Wu C, et al. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS PharmSciTech 2010;11:610-20.
18. Kumar JR, Muralidharan S. Formulation and in vitro evaluation of gellan gum/carbopol and sodium alginate based solution to gel depot of ketotifenfumarate system. J Pharm Sci Res 2012;4:1973-7.
19. Lena MT. Formulation and evaluation of floating oral in situ gel of metronidazole. Int J Pharm Pharm Sci 2014;6:265-9.
20. Doijad RC, Manvi FV, Malleswara VS, Alase P. Sustained ophthalmic delivery of gatifloxacin from in situ gelling system. Indian J Pharm Sci 2006;68:809-14.
21. Rathore KS. In situ gelling ophthalmic drug delivery system: An overview. Int J Pharm Pharm Sci 2010;2:30-4.
22. Kumar M, Kulkarni GT. Recent advances in opthlmic drug delivery system. Int J Pharm Pharm Sci 2012;4:387-94.
23. Shakta MS, Shalini A, Bharti C, Laxminarayan K, Rajadurai P, Rajdip LV. Effect of fucithalmic and sofinox eye drops on experimental allergic conjunctivitu in rats. Int J Pharm Pharm Sci 2014;6:458-60.
Statistics
66 Views | 9 Downloads
How to Cite
NIKITA PRADEEP KHANDELWAL, PRASHANT BHIDE, and REESHWA NACHINOLKAR. “FORMULATION AND EVALUATION OF SOLUBILITY ENHANCED IN SITU GELLING EYE DROPS OF LOTEPREDNOL ETABONATE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 12, Nov. 2019, pp. 209-16, https://innovareacademics.in/journals/index.php/ajpcr/article/view/33160.
Section
Original Article(s)